{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/increasing-engagement-and-collaborative-practices-two-phase-iii-oncology-trials#webpage",
"url": "https://www.fortrea.com/insights/increasing-engagement-and-collaborative-practices-two-phase-iii-oncology-trials",
"name": "Increasing engagement and collaborative practices in two Phase III oncology trials",
"description": "Explore this Fortrea Case Study highlighting how strategic patient recruitment planning, enrollment optimization, and collaborative study execution supported two Phase III immunotherapy oncology trials focused on lung cancer and skin cancer. The studies faced significant enrollment challenges due to restrictive eligibility criteria and inconsistent patient identification processes across participating institutions, limiting access to potential study participants and affecting recruitment efficiency. To overcome these barriers, Fortrea developed tailored patient mapping and site recruitment strategies that helped investigators identify eligible patients more effectively while improving coordination between surgical and medical oncology teams. The team also supported protocol amendment activities designed to expand eligibility criteria and increase opportunities for patient participation. Through enhanced collaboration among study sites, investigators, vendors, and stakeholders, Fortrea helped strengthen recruitment performance, improve enrollment outcomes, and support critical database lock milestones. This case study demonstrates how patient-focused recruitment strategies, enrollment optimization, protocol refinement, and cross-functional collaboration can help address complex enrollment challenges and accelerate the successful execution of Phase III immunotherapy oncology clinical trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Increasing engagement and collaborative practices in two Phase III oncology trials",
"item": "https://www.fortrea.com/insights/increasing-engagement-and-collaborative-practices-two-phase-iii-oncology-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/increasing-engagement-and-collaborative-practices-two-phase-iii-oncology-trials#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/increasing-engagement-and-collaborative-practices-two-phase-iii-oncology-trials#webpage"
},
"headline": "Optimizing Patient Recruitment and Enrollment in Two Phase III Immunotherapy Oncology Trials | Fortrea Case Study",
"description": "Explore this Fortrea Case Study highlighting how strategic patient recruitment planning, enrollment optimization, and collaborative study execution supported two Phase III immunotherapy oncology trials focused on lung cancer and skin cancer. The studies faced significant enrollment challenges due to restrictive eligibility criteria and inconsistent patient identification processes across participating institutions, limiting access to potential study participants and affecting recruitment efficiency. To overcome these barriers, Fortrea developed tailored patient mapping and site recruitment strategies that helped investigators identify eligible patients more effectively while improving coordination between surgical and medical oncology teams. The team also supported protocol amendment activities designed to expand eligibility criteria and increase opportunities for patient participation. Through enhanced collaboration among study sites, investigators, vendors, and stakeholders, Fortrea helped strengthen recruitment performance, improve enrollment outcomes, and support critical database lock milestones. This case study demonstrates how patient-focused recruitment strategies, enrollment optimization, protocol refinement, and cross-functional collaboration can help address complex enrollment challenges and accelerate the successful execution of Phase III immunotherapy oncology clinical trials.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-14",
"dateModified": "2026-04-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/phase-3-oncology-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}